Overview

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

Status:
RECRUITING
Trial end date:
2027-05-31
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of GB5005 in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL).
Phase:
PHASE1
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University